Showing posts with label NEJM. Show all posts
Showing posts with label NEJM. Show all posts

Good news for "Research Parasites": NEJM takes it back, 8 years later

After years of debate, the National Institutes of Health finally rolled out a data sharing policy early this year, one that should greatly increase the amount of data that biomedical researchers share with the public. This week, three prominent scientists from Yale described, in an op-ed in the New England Journal of Medicine, how “the potential effects of this shift ... toward data sharing are profound.”

For some of us, it’s deliciously ironic that this op-ed appeared in NEJM, which just a few years ago coined the term “research parasites” to describe anyone who wants to make discoveries from someone else’s data. That earlier piece, written in 2016 by the NEJM’s chief editors, was simply dripping with disdain. It caused a huge outcry, including a response from me in these pages and a sharply worded response from the Retraction Watch team, published in Statnews. The editor backed down (slightly) in a follow-up letter just a few days later, but the damage was done.

One interesting consequence was that a group of scientists created a Research Parasite Award, now awarded each year (entirely seriously, despite the tongue-in-cheek name) at a major biomedical conference, for “rigorous secondary data analysis.”

The 2016 op-ed in NEJM was itself a response to a call for greater data sharing published in the New York Times by cardiologists Eric Topol and Harlan Krumholz–and Krumholz, we should note, is a co-author of the latest piece in NEJM. Meanwhile, the former editor of NEJM retired years ago, and it appears that the journal is now ready to join the 21st century, even if it’s a few decades late.

What is all this fuss about? Well, many people outside of the scientific research community probably don’t realize that vast amounts of data generated by publicly-funded research–work that is paid for by government grants–are not usually released to the public or to any other scientists.

On the contrary: in much of biomedical research, data sets collected with government funding are zealously kept private, often forever. The usual reasons for this are simple (although rarely admitted openly): the scientists who collected the data want to keep mining it for more discoveries, so why share it? Sometimes, too, researchers package up the data and sell it, which is completely legal, even though the government paid for the work.

(It’s not just medical research data, either: once I tried to get some data from a paleontologist, only to learn that he treated every fossil he ever collected as his personal property. But that’s a blog for another day.)

Many scientists have been fighting this culture of secrecy for a long time. Our argument is that all data should be set free, at least if it’s the subject of a scientific publication. It’s not just scientists making this argument: since the early 2000s, patient groups began to realize they couldn’t even read the studies about their own diseases unless they paid a for-profit journal to access the paper. Those groups lobbied–successfully, after a years-long fight–that any publicly-funded research had to be published on a free website, not locked behind the doors of private publishers. Their effort led to an NIH database called PubMedCentral, which contains the full text of thousands of articles.

The new NIH data sharing policy is one consequence of the Open Science movement (which I’m a part of), which argues that science moves much faster when it’s done in the open. This means sharing data, software, methods, and everything else. There’s now a U.S. government website dedicated to Open Science, open.science.gov, which includes more than a dozen federal agencies including NIH, NSF, and the CDC.

A bit more history: as far as I can tell, the earliest voices for data sharing emerged during the Human Genome Project, an international effort beginning in 1989 that produced the first draft of the human genome in 2001. When a private company (Celera Genomics) emerged in 1998, a dramatic race ensued, and as one strategy for competing, the public groups announced that, in contrast to the private group, they would release all their data openly on a weekly basis, long before publication. That wasn’t how things had worked before.

Very soon after that, scientists in genomics (my own field) realized that all genome data, whether from bacteria, viruses, animals, or plants, ought to be released freely. The publicly-funded sequencing centers received millions of dollars to generate the data, but they weren’t the only places who could analyze it. NIH and NSF agreed, and pretty soon they required all sequencing data to be released promptly.

This same spirit didn’t touch most medical research, though. Even though far more money–billions of dollars a year in NIH funds–is spent on disease-focused research, data from those studies remained locked up in the labs that got the funds. This is now changing.

As the Yale scientists (Joseph Ross, Joanne Waldstreicher, and Harlan Krumholz) point out in their NEJM editorial, open data sharing has already yielded tremendous benefits. For example, they point out that hundreds of papers have been published using public data from the NIH’s National Heart, Lung, and Blood Institute, including studies that revealed new findings about the efficacy of digoxin, a common drug used to treat heart failure.

The new NIH policy covers all of NIH, not just one institute, and we can hope it will unlock new discoveries by allowing many more scientists to look at the valuable data currently kept behind closed firewalls.

But simply requiring scientists to have a “data management and sharing policy,” as the NIH is now doing, might not be enough. Many thousands of scientific papers already say they share data and materials–but as it turns out, the authors don’t always want to share.

A study published last year illustrated how toothless some current policies are. That study identified nearly 1800 recent papers in which the authors said they would share their data “upon request.” They wrote to all of them, only to find that 93% of the authors either didn’t respond at all, or else declined to share their data. That’s right: only 7% of authors shared their data, despite publishing a statement that they would.

The NEJM editorial proposes a different solution, one that could be far more effective: putting scientific data into a government repository. This is something the government itself can enforce (because they control the funding), and once the data is in a public repository, the authors won’t be able to sit on it as (some of them) now do.

It’s good to see NEJM joining the open science movement. Science that is shared openly will inevitably move faster, and everyone–except, perhaps a few data hoarders–will benefit.

No, You Still Don’t Need Vitamin D Supplements!

The NY Times this week ran a story under the headline “Am I Getting Enough Vitamin D During the Winter?” I’ll give you one guess how they answered that one.

Yes, the days are at their shortest right now. (The shortest day of the year will be Wednesday, December 21.) And yes, your body synthesizes vitamin D when you’re out in the sun, so you make less of it this time of year.

You also get vitamin D from a variety of foods. The Times story quoted a skin cancer expert from NYU School of Medicine, Dr. Deborah Sarnoff from, who said “you don’t need to get it [vitamin D] from sunshine.”

So you don’t need to run out and take vitamin D supplements. as I pointed out emphatically in a column I wrote back in August, and in several earlier columns too. Scientists have conducted multiple major studies of vitamin D supplements, as I wrote before, and those studies–involving thousands of subjects and running for many years–showed that

  • Vitamin D supplements do not improve bone density, and they do not reduce the risk of osteoporosis.
  • Vitamin D supplements don’t prevent heart disease, weight gain, mood disorders, multiple sclerosis, or metabolic disorders.
  • Vitamin D supplements (in the most recent study, involving 26,000 men and women followed for more than five years) don’t do anything to prevent bone fractures.

But the NY Times reporter (Rachel Peachman) really wanted to recommend supplements, it appears. She apparently wasn’t able to get a doctor to say that, so instead she quoted a dietitian nutritionist, who provided the quote, saying “Especially as we’re entering the winter months, most people would benefit from taking a supplement.”

Not surprisingly, the Times doesn’t quote an actual study that supports this recommendation, because that’s not what the science says. (To be fair, the dietitian also included some caveats, which are paraphrased in the article, including the point that “it’s difficult to suggest one blanket recommendation for everyone.”)

So no, NY Times, most people wouldn’t benefit from taking a supplement. As Drs. Steven Cummings and Clifford Rosen wrote last summer in the New England Journal of Medicine, “providers should stop screening for 25-hydroxyvitamin D levels or recommending vitamin D supplements, and people should stop taking vitamin D supplements to prevent major diseases or extend life.” And as five of my Hopkins colleagues wrote in a 2013 review in The Annals of Internal Medicine, “stop wasting money on vitamin and mineral supplements.” The science just doesn’t support it.

Cummings and Rosen also pointed out that more than 10 million blood tests for vitamin D levels are conducted in the US each year, with the vast, vast majority of these being unnecessary. These tests aren’t free, and our costly health care system doesn’t need the extra burden.

Finally, let me offer a caveat that I’ve written before: although routine supplementation is worthless and megadoses of vitamins can be harmful, if you think you have a vitamin deficiency, consult with your doctor. Serious vitamin deficiencies might be the result of other health problems that your doctor can help you address, and treatments for specific conditions or diseases may include vitamins.

Why the new COVID vaccine boosters are safe and likely very effective

In case you haven’t heard, there’s now a new set of vaccine booster shots that protect against the latest variant of Covid-19, BA.5. This new variant is highly infectious, and the original vaccine doesn’t protect people against it as well as it protected against earlier variants.

Now, before someone takes that last sentence out of context, let me emphasize that the original Covid-19 vaccines are still highly effective at preventing severe disease and hospitalization. Anyone who isn’t vaccinated would be well-advised to get one of those, if that’s their only option.

But the new vaccines protect against two different strains of Covid-19: the original strand and the latest Omicron variant, BA.5. BA.5 just emerged in August, and it’s spreading extremely fast–it now accounts for 88% of the cases in the U.S. The FDA authorized these “bivalent” boosters on August 31.

My main point today is to explain how this happened so quickly, and why it didn’t involve many months of clinical trials the way that the original vaccines did. Some people have expressed suspicion about the speed with which these boosters appeared, but those suspicions are entirely unfounded.

First of all, we do have data showing that the new vaccine boosters are safe: a study showing these data for the Moderna booster just appeared in the New England Journal of Medicine. That study also showed that people generated robust antibodies against the BA.1, BA.4, and BA.5 Omicron variants after getting the new booster.

Second, to explain why that’s all the data we need, let me explain something about the flu vaccine. Many people are well aware that we have a new influenza vaccine every year–but what they might not know is that each year’s vaccine contains a different strain of the flu virus from the previous year. (Actually, it has up to four different strains, and any or all of them could be new.)

And yet we don’t run large, months-long clinical trials of the flu vaccine each year to measure it’s efficacy. Why not? Well, the basic designs of the flu vaccines (there’s more than one) have been tested in large clinical trials, and we know they’re safe. Replacing the vaccine strain with a new one doesn’t affect the safety of the vaccine, as decades of experience with the flu vaccine have now demonstrated. And because flu mutates quickly, we need to change the vaccine strain every year if we want the vaccine to work.

So that’s what we do: we change the flu vaccine strain to match whatever seems to be circulating, but everything else about the vaccine design remains the same.

This is exactly what scientists have done with the new Covid-19 booster shots from Pfizer/BioNTech and Moderna: they simply added a new strain, in this case to match the latest Omicron variant.

Both of the new boosters are mRNA vaccines, which means the vaccine contains a tiny bit of genetic code (mRNA) with instructions on how to make the “spike” protein from SARS-CoV-2, the Covid-19 virus. When you get the vaccine, your own cells follow those instructions to make a limited number of copies of the spike protein–but nothing else. The virus itself can’t be created without many other genes, and the spike protein alone can’t form a virus.

But your immune system recognizes that an invader is present–that spike protein–and it generates antibodies against it. After that, your immune system is primed to recognize and defeat Covid-19, if it ever infects you.

So the new boosters contain mRNA from the BA.5 spike protein as well as the original spike protein, and now you get protection from both old and new strains. Other than that, it’s the same vaccine as before.

The vaccine makers have produced safety data showing that the booster is just as safe as the original vaccine (see that NEJM article I mentioned above). But the FDA didn’t require them to prove that the booster really works better against BA.5, because that would require months of trials, and by that time the virus could mutate again. So while it’s possible that the boosters won’t help against BA.5, it’s very, very likely that they will.

One of the big advantages of mRNA vaccines is precisely this: we can swap out the mRNA easily, allowing us to respond quickly to mutations in circulating viruses. That’s a good thing, and it might be our only path to controlling Covid-19.

The bottom line is that the new boosters should be very safe, and they will likely provide much better protection against the current strains of the Covid virus. I’ve already gotten my booster, and I hope everyone else will too.

For Pete's Sake, Stop Taking Vitamin D Supplements!

Way back in 2014, I wrote a column about vitamin D supplements, explaining that they don’t work. I added vitamin D to my previous list, the Top 5 Vitamins That You Should Not Take, to create a list of 6 useless vitamin supplements.

Together, these two columns had well over 1,000,000 views. And yet it seems the message didn’t get through. Well, now a massive new study published in the New England Journal of Medicine reports that I was right all along: taking vitamin D pills isn't good for you. Let’s review the findings, shall we?

In 2014, I wrote about two studies, both published in The Lancet. The first paper, a massive review of 462 other studies, concluded that taking supplemental vitamin D did not help to prevent heart disease, weight gain, mood disorders, multiple sclerosis, and metabolic disorders, all of which had been linked to lower vitamin D. Nope, they said: it appears that low levels of vitamin D are a result of bad health, not the cause.

Ah, you might be thinking, but vitamin D is mostly about bone health, right? Well, the second study that I wrote about in 2014 looked precisely at that question. That paper concluded that vitamin D supplements do not improve bone density, and they do not reduce the risk of osteoporosis.

In other words, vitamin D supplements are a complete waste of money.

Nonetheless, people keep taking vitamin D, and doctors in the U.S. continue to recommend it (based on published guidelines that urgently need revision), on a very large scale.

So now we’ve spent millions of dollars on a huge new trial, which followed nearly 26,000 men and women for more than 5 years, to see if vitamin D supplements would do anything to prevent bone fractures. (And by “we” I mean U.S. taxpayers, who funded this study through grants from the National Institutes of Health.)

The result: people who took vitamin D had exactly the same risk of bone fractures as those who didn’t. It didn’t matter how much vitamin D they took, nor did it help if they also took supplemental calcium at 1200 mg per day. And it didn’t help people who had relatively low levels of vitamin D either. Taking vitamin D supplements just didn’t make any difference to anyone.

So we should stop taking vitamin D–but there’s more. In an editorial accompanying the new study, Steven Cummings and Clifford Rosen point out that “More than 10 million serum 25-hydroxyvitamin D tests are performed annually in the United States.” These tests add costs to our already exorbitant health care system, and they don’t provide patients with any benefit.

Cummings and Rosen put it bluntly: “providers should stop screening for 25-hydroxyvitamin D levels or recommending vitamin D supplements, and people should stop taking vitamin D supplements to prevent major diseases or extend life.” Or as my Hopkins Eliseo Guallar, Lawrence Appel, and Edgar Miller wrote back in 2013, “Enough is enough: stop wasting money on vitamin and mineral supplements.”

At the top of this article I mentioned that my list of useless vitamin supplements has 6 vitamins on it, so here they are:

  1. Vitamin C
  2. Vitamin A and beta carotene
  3. Vitamin E
  4. Vitamin B6
  5. Multi-vitamins
  6. Vitamin D

If you want to know the science behind the other 5, take a look at my column on The Top Five Vitamins You Should Not Take.

Finally, I should point out that although routine supplementation is worthless and megadoses of vitamins can be harmful, if you think you have a vitamin deficiency, consult with your doctor. Serious vitamin deficiencies might be the result of other health problems that your doctor can help you address, and treatments for specific conditions or diseases may include vitamins.

A new kind of fasting provides significant immune system benefits

I've written about fasting and its effects on health before. Six years ago, a study showed that a 3-day fast can essentially reset the immune system, providing many potential benefits. These benefits include better cardiovascular health, better endurance, lower blood pressure, and reduced inflammation.

Newer data, which I'll get to in a minute, shows that you might not have to fast nearly that long to get these benefits.

In the 2014 study, Valter Longo and colleagues at USC found that fasting lowered white blood cell counts, which in turn triggered the immune system to start producing new white blood cells. White blood cells (or lymphocytes) are a key component of your body’s immune system. Once you start eating again, according to Longo, your stem cells kick back into high gear to replenish the cells that were recycled.

The idea behind this strategy is that you have to fast for several days to get the benefits: basically, you have to fully deplete your energy reserves (in the form of glycogen), and it takes your body at least 24 hours, and probably 48 hours or more, to do this. That's the not-so-good news. The good news is that you probably only need to fast once or twice a year to gain the benefits that Longo described.

Last week, in a paper just published in the New England Journal of Medicine, Rafael de Cabo and Mark Mattson reviewed multiple strategies for fasting that have been tested in the years since Longo's study. The news continues to be very encouraging: intermittent fasting is good for you. I don't have time or space here to discuss all the results, but I want to focus on one fasting strategy that has surprisingly good benefits.

It turns out that you can get many of the benefits of fasting without doing a 3-day fast, which for most people is really, really difficult to accomplish. Instead, you can try a much easier type of fasting, called "time-restricted" fasting. With this strategy, you fast every day, by eating all of your food in a 6-hour or 8-hour window. Or you can go with the more difficult strategy (but still easier than a 3-day fast) where you fast for 2 entire days per week. Here, then, are two intermittent fasting strategies that have similar health benefits:

  • Time-restricted: eat lunch starting at 12 noon, and finish dinner by 8:00pm. Fast until the next day at noon (16 hour fast). Do this every day.
  • 5:2 fasting: fast for 2 different days each week, which means eating just 500-700 calories worth of food and drink on those days. Eat normally on the other 5 days.

The first strategy–a daily 16-hour fast–is the easiest, but its benefits might be equal to those of 5:2 fasting and the 3-day fast. (No study has directly compared these 3 fasting regimens.)

The benefits of intermittent fasting are numerous. As de Cabo and Mattson explain, they include
"[improvements in] blood pressure; resting heart rate; levels of HDL and LDL cholesterol, triglycerides, glucose, and insulin resistance.... In addition, intermittent fasting reduces markers of systemic inflammation and oxidative stress that are associated with atherosclerosis."
Fasting also helps with weight loss, for obvious reasons. Cutting out all snacks in the evening, which is the biggest change imposed by time-restricted fasting, means not only a reduction in calories consumed, but also a reduction in the amount of highly processed ("junk") foods in one's diet as well.

Furthermore, because intermittent fasting reduces inflammation, it may also improve symptoms of arthritis and even rheumatoid arthritis.

Why does fasting work? It's all about getting your body to switch over from glucose metabolism to ketone metabolism. Our usual 3-meal-a-day diet provides our body with a constant source of fuel in the form of glucose. Once that glucose is used up, though, our body switches to using fatty acids and ketone bodies. Ketone bodies provide more than fuel: as de Cabo and Mattson explain,
"Ketone bodies regulate the expression and activity of many proteins and molecules that are known to influence health and aging."
Ketone metabolism seems to bring a host of health benefits. The trick is getting our bodies to switch over to it, now and then. If we eat constantly, then our bodies happily subsist on glucose and never make the switch.

Does fasting truly reset your immune system? Six years ago, I concluded that a 3-day fast does the trick, at least partially. The science suggests that, if you can do it, a prolonged fast for 2-3 days will induce your body to clean out some old immune cells and switch on production of new ones. Now we're learning that intermittent fasting, which is easier to do, may work in much the same way, with multiple health benefits.

[Note: one of the authors of the NEJM study, Mark Mattson, is a Professor at Johns Hopkins School of Medicine, making him a colleague of mine. However, we are in different departments and we have never met.]

Can the Apple Watch monitor heart health?

Can the Apple Watch accurately detect atrial fibrillation?

When I first heard that scientists were conducting a study to answer this question, I was deeply skeptical. A simple wrist device detecting heart arrhythmias? This seemed too simplistic to be possible.

But a new study, just published in the New England Journal of Medicine, lays out some pretty compelling evidence that the Apple watch can do just that.

Atrial fibrillation (or atrial flutter) is a type of irregular heartbeat that is the most common cardiac arrhythmia in the U.S., affecting some 6 million people a year. The NEJM article estimates that the lifetime risk for "a-fib" might be as high as 1 in 3. Atrial fibrillation isn't necessarily a problem on its own, but it can greatly increase the risk of strokes. Many people have episodes of a-fib without even being aware of them, which is why a simple, convenient way of detecting them could be medically valuable.

The Apple Watch study was truly enormous, with 419,297 subjects monitored for about 4 months. Only a company like Apple, with a popular product like its watch, can even hope to recruit this many people to join a study. The idea was pretty simple: use the Apple Watch to detect an irregular pulse, which might be sign of atrial flutter or arrhythmia.

During the course of the study, 2,161 subjects had at least one report of an irregular pulse, about 0.5% of the total. Each of these subjects was then sent an electrocardiogram (ECG) patch, which they were supposed to wear for several days to determine if they really were having arrhythmias.

Of course, not everyone wore the ECG patch as they were supposed to, but in the end, 450 subjects wore the ECG patch (for an average of about 6 days), filled in all the required questionnaires, and returned the patch for analysis. Among these subjects, 34% of them genuinely did have atrial fibrillation as confirmed by the ECG patch. Some of them had only brief episodes, but a subgroup had nearly continuous symptoms.

The study also tried to determine the false positive rate of the Apple Watch warnings–that is, how often did it report an irregular pulse when the subject was not experiencing a-fib or atrial flutter? The researchers evaluated all of the reports from watches that were being worn by people who also had an ECG patch. In this analysis, 71% of the irregular pulse reports from the watch corresponded to atrial fibrillation simultaneously measured by the ECG patch. The other 29% weren't normal either: three-fourths of those reports were due to "frequent premature atrial contractions."

So overall, the Watch was surprisingly accurate, with an impressively low false positive rate.

How does it work? Well, the back of the watch contains several sensors that detect light (photodiodes), along with green and infrared LEDs that emit light. As Apple's website explains,
"By flashing its LED lights hundreds of times per second, Apple Watch can calculate the number of times the heart beats each minute."
This works because your skin is partially transparent: as everyone knows, you can see some of your blood vessels underneath your skin. In addition to measuring blood flow, the watch can also measure electrical signals using electrodes on the back of the watch and on a small dial on the side of the watch, called the Digital Crown. Here's how Apple explains this:
"When you place your finger on the Digital Crown, it creates a closed circuit between your heart and both arms, capturing the electrical impulses across your chest."
In other words, it behaves like an ECG monitor on your wrist. The NEJM study didn't use this feature of the Apple Watch, which suggests that the watch could be even more effective as a heart monitor in the future.

The Apple Watch is far from perfect, though. For one thing, we don't know how many episodes of atrial fibrillation it missed. Only 0.5% of subjects had a report of irregular pulse, but we don't know how many of the remaining 99.5% had an episode that the watch didn't detect. The authors of the study pointed out that they weren't trying to measure the watch's sensitivity, and they emphasized that
"the absence of an irregular pulse notification does not exclude possible arrhythmias."
Another caveat is that the study was funded by Apple, although it was led by scientists at Stanford and included scientists from multiple other highly regarded universities and medical schools. The funding was clearly disclosed in the NEJM article.

On the other hand, using the Apple Watch is far easier than other currently available procedures for monitoring your heart. Patients who have episodes of arrhythmia are typically told to wear a heart-rate monitor for days or weeks at a time. This involves taping electrodes to half a dozen places on your body, all of which are connected by wires to a device (basically a cell phone) that records the readings and sends them to a monitoring company. These monitors are very expensive to operate, far more than the Apple Watch.

So despite its imperfections, the Apple Watch might be the vanguard of a new wave of lightweight, less intrusive devices for monitoring our health. The technology is only going to get better.

NEJM says open access is unnecessary. Right.

Surprise: the New England Journal of Medicine thinks open access is a bad idea. Open access is the model of scientific publishing in which all results are freely available for anyone, anywhere, to read.

This week NEJM published an editorial by one of their correspondents,  Charlotte Haug, that purports to present an objective look at open access publishing, and finds that the "experiment" has failed, and that free access to scientific publications hasn't delivered on its promises.

What is NEJM worried about? Their expensive, exclusive model of publishing–where everyone has to pay high subscription fees, or else pay exhorbitant fees for each article they read–is threatened by scientists who want all science to be free. Pesky scientists!

NEJM is especially worried about "Plan S", a proposal in Europe to require that all scientists whose work is funded by the public be required to publish their results in open-access venues. Plan S is due to take effect very soon, in 2020 for 11 research funders in Europe.

The NEJM article is a clever but deeply flawed effort to prove that open access isn't working. It's full of fallacies and straw men, so much so that it's hard to know where to begin. Since they're not playing fair, though, I won't either: I'll cherry-pick three of Haug's arguments and explain why she's wrong about each one.

But first, to set the stage, let's remind everyone of what we're talking about. Scientific papers are written by scientists (like me), who are largely funded to do their work by governments, non-profit organizations, and occasionally by commercial companies. The writing is done by the scientists themselves, who submit papers to journals for peer review. The peer reviewing is also done by scientists (again, like me) who do this work for free. The journals pay nothing for all this work.

In other words, we do all the work for free, using funding provided by the public, and the journals then take that work and sell it for a very tidy profit. (Richard Smith estimates that NEJM itself has an income of $100 million with a 30% profit.) The vast majority of scientific and medical journals are owned by five for-profit corporations, as the NEJM points out:
"The five largest publishing houses (SAGE, Elsevier, Springer Nature, Wiley-Blackwell, and Taylor & Francis) continue to grow, with high profit margins."
For the past two decades, scientists have spoken out more and more over the outrageous practices of for-profit publishers, whose subscription fees and profits have grown while the costs of distribution have plummeted. Virtually everyone gets scientific papers online now. Why sign over copyright when we can distribute our work so cheaply now? The open access movement was founded to provide an alternative: open access journals allow everyone to read all the content for free, and the authors retain their copyrights.

Now let's look at the NEJM article. Haug starts by pretending to agree that open access is a good thing, writing:
"The idea — that the results of research should be available to be read, discuss, and examine... — has few, if any, opponents in either the scientific community or the public."
Reading this, you might think that Haug (and NEJM, by extension) are fans of open access. They are not.

Haug then proceeds (she thinks) to dismantle the arguments in favor of open access. First, she states that publishing costs have not dropped, but have increased. As evidence, she asserts that "Electronic production and maintenance of high-quality content are at least as expensive as print production and maintenance." This claim is, frankly, nonsense, but since Haug doesn't cite any evidence to back it up, there's nothing really to refute. It's obviously much cheaper to post a PDF on a website than to print thousands of hardcopies and physically ship them to libraries around the world. If costs are going up (and again, Haug cites no evidence), that could be simply because publishers are paying themselves higher salaries (NEJM reported compensation of  $703,324 for its chief editor in 2017), or hiring large staffs, or renting luxurious offices–who knows? Haug doesn't explain.

In any case, the costs of publishing at NEJM, a closed-access, subscription-based journal, have little to do with whether or not scientific and medical research should be freely available.

Her next argument against open access is that the most highly-cited journals are subscription-based, like (ahem) NEJM. My response: so what? Everyone within academia knows that it takes a very long time to establish a reputation as a "top" journal, and young scientists will always want to publish in those journals, regardless of how expensive they are. This has given closed-access journals like NEJM (and Nature, Science, JAMA, and Cell, to name a few more) tremendous power, which they have wielded to fight against open access at every opportunity. This editorial represents another example of that fight. The fact that many scientists still want to publish in these journals doesn't mean they should keep the results locked behind a paywall.

Setting aside this tiny number of "prestige" journals, open access papers do get cited more, as was demonstrated by this study from 2016. The evidence shows that open access does lead to higher impact: papers that are freely available are read more and cited more.

Finally, let's turn to Haug's coup de grace, which she wields near the end of her piece, as a sort of "proof" that open access is really unnecessary. Here she argues that NEJM is already open, mostly:
"About 98% of the research published in the Journal since 2000 is free and open to the public. Research of immediate importance to global health is made freely accessible upon publication; other research articles become freely accessible after 6 months."
First, let's acknowledge that merely by pointing this out, Haug is admitting that the main arguments for open access are legitimate; i.e., that it's a huge benefit to society to make research freely available. I'm going to agree with her here.

What Haug doesn't mention here is that there is one reason (and only one, I would argue) that NEJM makes all of its articles freely available after some time has passed: the NIH requires it. This dates back to 2009, when Congress passed a law, after intense pressure from citizens who were demanding access to the research results that they'd paid for, requiring all NIH-funded results to be deposited in a free, public repository (now called PubMed Central) within 12 months of publication.

Scientific publishers fought furiously against this policy. I know, because I was there, and I talked to many people involved in the fight at the time. The open-access advocates (mostly patient groups) wanted articles to be made freely available immediately, and they worked out a compromise where the journals could have 6 months of exclusivity. At the last minute, the NIH Director at the time, Elias Zerhouni, extended this to 12 months, for reasons that remain shrouded in secrecy, but thankfully, the public (and science) won the main battle. For NEJM to turn around now and boast that they are releasing articles after an embargo period, without mentioning this requirement, is hypocritical, to say the least. Believe me, if the NIH requirement disappeared (and publishers are still lobbying to get rid of it!), NEJM would happily go back to keeping all access restricted to subscribers.

The battle is far from over. Open access advocates still want to see research released immediately, not after a 6-month or 12-month embargo, and that's precisely what the European Plan S will do.

With Plan S looming, I've no doubt we'll see more arguments against open access in the coming months, but scientists have at least one ace up our sleeves: we're the ones who do all the work. We do the experiments, we write the papers, and we review the papers. Without us, the journals would cease to exist. The journals will have no choice but to go along with plan S, because without the scientists, they'll have nothing to publish. Let's hope the U.S. will follow suit in the very near future. It's long past time to change the archaic, closed-access policies that have kept medical and scientific results–results that were funded by the public–locked behind the paywalls of for-profit publishers.

Anti-vaxxers use religious exemptions as false cover for their beliefs

History of measles in the 20th century.
For several years now, anti-vaxxers have been claiming that they have religious objections to vaccines. This is nonsense.

Just last month, the New England Journal of Medicine featured an article describing how the federal Equal Employment Opportunity Commission (EEOC) has been suing hospitals that deny employee requests for religious exemptions to the hospitals' vaccination requirements. The NEJM documented 14 cases where employees sued claiming that they had religious objections to the flu vaccine. Six of the cases were settled, and in the other cases, sometimes the hospital won, sometimes the employees. It's a mess.

The NEJM article focused on the legal perspective, advising hospitals on how they might avoid lawsuits. That's understandable, but it misses the broader point: there's virtually no such thing as a religious objection to vaccines. All of the world's major religions support vaccination, and only a few tiny, extremist sects teach their followers that vaccines are contrary to their faith.

What's really going on is that anti-vaxxers are using religious exemptions as cover for non-religious (and erroneous) objections to vaccines. The anti-vaxxers have convinced people that vaccines are harmful, or scary, or both. They are wrong.

Vaccines are the probably the greatest success story in the history of medicine. They've saved millions of lives. Consider that in the decade before the measles vaccine was introduced in 1963,
"3 to 4 million people in the United States were infected each year [and] an estimated 400 to 500 people died, 48,000 were hospitalized, and 1,000 suffered encephalitis (swelling of the brain) from measles." (Source: CDC)
And that's just measles. People no longer suffer and die from smallpox and polio, which have been eradicated worldwide (except for a few countries where polio still has a foothold). Vaccines protect us from multiple other formerly common childhood infections, and they've been so effective that people are no longer afraid of these diseases. That very success is the opening that the anti-vaxxers use to spread disinformation and fear.

It's not just the EEOC that has been enabling anti-vaxxers. Many U.S. states have passed laws that allow religious exemptions to vaccination. (Note that vaccines are required before children can enroll in public school systems, an incredibly important public health requirement. The exemptions refer to this requirement.)

Here, though, there are signs of hope. After suffering from repeated outbreaks of preventable diseases like measles, many states have recently awakened to the risks caused by unvaccinated children in public schools, and they are moving to remove or tighten these exemptions.

New Jersey is the latest state to act. While the bill introduced in the New Jersey legislature last week doesn't quite eliminate religious exemptions, it makes them harder to get, requiring considerably more documentation from parents claiming a religious exemption from vaccines for their children. NJ took action after realizing that these so-called "religious" objections had risen dramatically, from 3,865 in 2009 to 10,407 in 2016. That rise was fueled, apparently, by anti-vaxxers taking advantage of the loophole in the law, not by any genuine religious objection to vaccines.

It's worth noting that all states allow medical exemptions to childhood vaccination, which are legitimate and necessary. For example, a child undergoing leukemia treatment may have a severely weakened immune system, and a vaccine would be ineffective and possibly harmful. These children are precisely the ones who can only be protected by requiring all the other children in their school to be vaccinated.

Meanwhile, the EEOC should stop suing hospitals. Hospitals are filled with very sick and vulnerable people, and employees have an obligation not to expose patients to possibly deadly infections. If a hospital employee doesn't take that obligation seriously, then s/he should find another job.

Guys: you don't need a PSA test for prostate cancer

Graphic depiction of risk without or with PSA tests, from
the Harding Center for Risk Literacy.
I learned a new word this week: pseudoepidemic. That's what happens when people start looking really hard for a disease that didn't get much attention earlier, and then–not surprisingly–the disease suddenly becomes much more prevalent.

This is precisely what happened with prostate cancer in the early 1990s, just after screening tests for prostate-specific antigen (PSA) became widely available. As explained by NIH's Paul Pinsky and colleagues in an article in the New England Journal of Medicine this week, prostate cancer rates rose from 135 (cases per year, per 100,000 men) in 1988 to 220 in 1992, a 63% increase in just four years. Rates slowly dropped after that, but they remained above 150 through 2009.

No one believes that this increase represented an actual increase in the rate of prostate cancer. Instead, it was an increase in the rate of diagnosis, made possible by the PSA test. After this simple blood test became available, millions of men started getting routine PSA testing. The idea was that, because prostate cancer increases the levels of PSA in the blood, this test could detect cancer early, which in turn would save lives.

It hasn't worked out that way. The problem is that, as a large body of evidence has now shown, most prostate cancers are slow-growing, "indolent" tumors that don't kill you, at least not before something else does.

What's worse is that the treatments for prostate cancer have very serious, life-altering side effects. 20-30% of men treated with surgery and radiation suffer from long-term incontinence, erectile dysfunction, or both.

This is especially problematic given that the false-positive rate of PSA testing is as high as 80%. In other words, if your doctor tells you that your test was positive, there's an 80% chance that you don't have cancer. Many men, though, elect for further, much more invasive testing after a positive result, because who can sleep at night without knowing for certain?

But how about the benefits of early detection? Alas, they did not materialize. Very large trials (including the PLCO study, with over 75,000 participants) showed that routine PSA screening did not prevent any deaths. The only study to show any benefit, ERSPC, had serious flaws, as explained by Ian Haines and George Miklos in the Journal of the National Cancer Institute.

Putting all these facts together, the US Preventative Services Task Force concluded that the harms of PSA testing substantially outweigh the benefits, and it recommends, bluntly:
"Do not use prostate-specific antigen (PSA)-based screening for prostate cancer."
The American Academy of Family Physicians agrees, stating:
"There is convincing evidence that PSA-based screening leads to substantial over-diagnosis of prostate tumors. Many tumors will not harm patients, while the risks of treatment are significant. Physicians should not offer or order PSA screening unless they are prepared to engage in shared decision making that enables an informed choice by patients."
Even the American Urological Association, which strongly opposed the USPSTF recommendation when it first appeared, now recommends against PSA screening except in one age group, men 55-69 years old. The AUA, though, is highly biased in favor of testing, because its members make significant income from PSA tests and the subsequent follow-ups.

Prostate cancer is a very serious disease among older men. According to the American College of Physicians, 1 out of 16 men will receive a diagnosis of prostate cancer in their lifetimes, although only 2.9% will die of it, most of them older than 75. Nonetheless, PSA screening does not help: it carries a significant risk of harm. In this week's NEJM article, Pinsky et al. conclude:
"Under the `first do no harm principle,' it seems reasonable to forgo mass screening as a public health policy at this point."
Someday we may have a better test for prostate cancer, but for now, we don't. If your doctor offers you a PSA test, your best response is probably to tell him no thanks.

[Aside: the article in the New England Journal of Medicine was written by scientists from the National Cancer Institute at NIH, yet it's behind a paywall that prevents anyone from reading it without paying a costly fee or an even more expensive subscription to the journal. Why do we have to pay a fee to read work that the taxpayers already paid for?]

Clinical trials doctors claim they own patients' data, want others to pay for access

Image from "Honoring our promise: clinical trial data sharing"
at the NIH Director's blog.
Earlier this month, a consortium of 282 clinical trials doctors, in an article in the New England Journal of Medicine, threw down the gauntlet against the notion that they should share data. Under the misleading title “Towards fairness in data sharing,” these scientists, who label themselves The International Consortium of Investigators for Fairness in Trial Data Sharing, put forward the breathtakingly arrogant claim that doctors who collect data from patients should control it essentially forever.

I wonder what their patients would think if they knew.

This is the second salvo from NEJM this year. Back in January, the editors of NEJM published an opinion piece that used the derogatory phrase “research parasites” to describe scientists who want to re-analyze data from other scientists’ experiments. This caused an outcry, with many scientists pointing out serious flaws in the editors’ arguments. As I wrote at the time,   
“Drazen and Longo [the NEJM editors] are saying, essentially, that only the people who originally collect a data set can truly understand it, and anyone else who wants to take a look is a parasite.”
Keeping scientific data locked away is a recipe for bad science. In the absence of data sharing, flawed results may go unchallenged for years. If someone has distorted or misinterpreted data, we need someone else–someone not invested in proving the same result–to take a second look. This is how science corrects itself.

Even so, at least Drazen and Longo endorsed some data sharing. The authors of this new article (P.J. Devereaux, Gordon Guyatt, Hertzel Gerstein, Stuart Connolly, and Salim Yusuf, all from Ontario’s McMaster University) and their consortium are vehemently opposed to sharing their data with anyone, ever.

Let’s go through their arguments. First, they point out that it takes years of work to set up and run a clinical trial. Absolutely right–no argument there. But then they explain why they conduct these trials:
“A key motivation for investigators to conduct RCTs is the ability to publish not only the primary trial report, but also major secondary articles based on the trial data. The original investigators almost always intend to undertake additional analyses of the data and explore new hypotheses.”
Oh really? This is why they run clinical trials, in order to publish papers? Somehow I doubt that is what they tell the patients as they are asking for informed consent. Not “we want to figure out what is making you sick” or “we want to find a cure”, but “we want to publish a paper, or maybe several papers!” I’m sure that patients would be lining up around the block to join these studies.

Don’t get me wrong: of course the scientists want to publish their findings, and of course they would like to mine the data for more papers, year after year. That’s what some investigators do now. In this world, doctors running clinical trials would never share data. Why would they, when things are working so well for their careers?

But they seem to have forgotten THE motivation for clinical trials: curing disease. I am honestly dumbfounded that Devereaux and his colleagues don’t mention the words “disease” or “illness” in their article, not even once. Instead they focus on “risks” of sharing data, by which they mean the risk that someone else will make a discovery that they didn’t think of, versus the “benefits,” which in their world means either confirming the original study or possibly testing a new hypothesis. They seem oblivious to the notion that re-analyzing the data to contradict the original claims might actually be a benefit to the rest of the world.

Appalling. Did they feel this way when they first went into medical research? Probably not, but somewhere in the competitive struggle to succeed as researchers, they lost their way.

It gets worse. Devereaux and his consortium go on to lay out what they might be willing to consider:
  • Exclusive use of the data for a minimum of 2 years after the first publication
  • Another 6 months of exclusivity for every year the trial lasted, up to 5 years of exclusivity
  • Anyone who wants the data should pay the original investigators “for their efforts and investments in the trial.”
This last point is the most outrageous of all. Hello? Investigators in clinical trials are already paid for their efforts (though the patients are not), often totaling millions of dollars, and often from taxpayers’ money. Now they want to be paid again by each scientist who wants to look at the data?

These guys need to get over it. The reason we fund clinical trials is to cure disease, not to allow Devereaux and company to publish papers. Publication is the means by which we communicate results, but it’s not the reason that anyone pays for the experiments.

Interestingly, in the same issue of NEJM, U.S. Senator Elizabeth Warren writes about data sharing, expressing quite the opposite view from Devereaux and company. I won’t attempt to summarize her points here, but instead let me quote from one of the public comments published in response to the anti-data-sharing doctors:
“ `This is not working. I just hope that my death will not be in vain and someone learns from it so that others don't have to go through this’ was what my husband said when it became clear that the new drug combination was not working fast enough for us…. My husband died now more than 4 years ago. I have watched his and others' lives been plotted on curves at conferences like ASCO or EMSO and it is deeply upsetting that there are more than 280 researchers who are more concerned about their own careers than the lives of the patients on whom those careers are built. Claiming rights to data paid for with the lives of others has nothing to do with fairness.” Bettina Ryll, M.D., Ph.D., Melanoma Patient Network Europe
I couldn’t say it any better than that. The International Consortium of Investigators for Fairness in Trial Data Sharing–as the 282 investigators called themselves–should be ashamed.